Related Experiment Video

Updated: Jul 17, 2026

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

Regulation of tumor signaling pathways by AZD3409 in vitro

Robert Streeper1, David Campos, Gilbert Carrizales

  • 1Cancer Therapy and Research Center, Institute for Drug Development, San Antonio, TX 78245 USA.

Anticancer Research
|January 5, 2007
PubMed
Abstract

Insights

AZD3409 demonstrates antineoplastic activity by inhibiting farnesylation, impacting cancer cell growth and survival pathways. Its effects on biomarkers vary between breast and ovarian cancer cell lines.

Area of Science:

  • Pharmacology
  • Cancer Biology
  • Molecular Oncology

Background:

  • Investigating the antineoplastic potential of AZD3409 against human breast and ovarian cancer.
  • Comparing AZD3409's efficacy with paclitaxel in selected cancer cell lines.
  • Assessing key biomarkers related to apoptosis, protein prenylation, survival, angiogenesis, and cellular growth.

Purpose of the Study:

  • To evaluate the antineoplastic activity of AZD3409.
  • To determine the effects of AZD3409 on specific cellular pathways.
  • To understand the mechanism of action of AZD3409 in cancer cells.

Main Methods:

  • Cytotoxicity assessed using MTS assay.
  • Apoptosis evaluated via TUNEL assay.
  • Biomarker analysis conducted through Western blots and ELISA.

Main Results:

  • AZD3409 exhibited varying IC50 and EC50 concentrations across breast (MDA-MB-231, BT-474) and ovarian (A2780, A2780cp) cancer cell lines.
  • Famesylation of HDJ-2 was inhibited in all tested cell lines.
  • Differential effects observed on VEGF, bFGF, MMP-1 secretion, and Akt activation between breast and ovarian cancer cells.

Conclusions:

  • AZD3409's cytotoxicity is partly mediated by the inhibition of farnesylation.
  • The drug impacts angiogenesis and survival pathways differently in breast versus ovarian cancer.
  • AZD3409 presents a potential therapeutic strategy targeting specific cancer types.

More Related Videos

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Related Concept Videos

Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...